Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. Its cardiometabolic health portfolio includes Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. The company also offers oncology products such as Cyramza, Erbitux, Inluriyo, Jaypirca, Retevmo, TYVYT, and Verzenio, as well as immunology products including Ebglyss, Olumiant, Omvoh, and Taltz. Additionally, it provides Emgality for migraine prevention and episodic cluster headache, and Kisubla for symptomatic Alzheimer's disease. Eli Lilly has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab; license agreements with Almirall, S.A. for Ebglyss and Chugai Pharmaceutical Co., Ltd for orforglipron; a strategic collaboration with Ascidian Therapeutics for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for a new treatment. Founded in 1876, Eli Lilly and Company is headquartered in Indianapolis, Indiana.
Lilly hits record on Medicare obesity coverage and cancer drug progress
▲
Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.
This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.
▲
Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.
New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.
▲
Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.
Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.
▲
Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.
Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.
Latest
▲3▼1
Lilly's pipeline wins and Foundayo growth offset Novo's competitive threat
▲
Foundayo captures one-third of new oral GLP-1 patients Lilly's oral weight-loss pill Foundayo now accounts for about one-third of new patients starting oral GLP-1 medicines, with market share rising weekly. This shows real commercial traction, supporting future sales growth and reinforcing Lilly's obesity franchise.
Demonstrates Foundayo's rapid adoption, a key growth driver for Lilly's obesity business.
▲
Retatrutide delivers up to 20.8% weight loss in Phase 3 Lilly's next-generation obesity drug retatrutide helped patients lose up to 20.8% of body weight in a Phase 3 trial, with many no longer meeting obesity criteria. This strengthens Lilly's pipeline and future growth prospects beyond current drugs.
Positive clinical data for a key pipeline asset boosts long-term revenue potential.
▲
Foundayo cuts cardiovascular risk in large trial Foundayo reduced heart risks by 16% versus insulin in a major trial, with lower death rates. This could expand its use to heart patients, boosting sales and differentiating it from competitors.
Cardiovascular benefit expands Foundayo's label potential and market reach.
▼
Novo's CagriSema beats Lilly's tirzepatide in head-to-head Novo Nordisk's CagriSema helped patients lose 12.4% weight versus 9.1% for Lilly's tirzepatide in a Phase 3 trial. This competitive threat could slow Lilly's market share gains if CagriSema wins approval.
Direct competitive loss in a key trial poses a risk to Lilly's obesity leadership.
Q3 2026
▲2▼2
Lilly hits $1T on obesity demand, but competition and coverage risks rise
▲
Obesity drug demand drives record revenue and $1T valuation Revenue jumped 47.7% to $22.97 billion, with Mounjaro sales up 91%, pushing Lilly past a $1 trillion market value. The company raised its financial guidance, showing the obesity-drug boom is still accelerating.
This is the core positive force behind Lilly's price surge in Q3.
▲
Pipeline and access expand Lilly acquired AtaiBeckley, reported positive Alzheimer's data, won cancer and insulin approvals, and expanded access to its oral GLP-1 Foundayo through Amazon and CVS. A new $6.5 billion Houston plant will boost supply.
These moves broaden Lilly's product lineup and make its drugs easier to get, supporting future growth.
▼
Competition intensifies as Novo Nordisk scores wins Novo Nordisk won EU approval for oral Wegovy, and its CagriSema beat Zepbound in a head-to-head trial (12.4% vs. 9.1% weight loss). This threatens Lilly's dominance in the obesity market.
Rising competition is a key risk that could pressure Lilly's market share and pricing.
▼
Regulatory and coverage headwinds mount Retatrutide's FDA filing slipped to 2027 due to a heart-event imbalance, Germany's rebate reform led to manufacturing cuts, and about 14% of US employers plan to drop GLP-1 coverage by 2027.
These setbacks could delay a key drug and reduce future sales, weighing on investor sentiment.
News & notes movingLLY
United States
Biotech & Genomic Medicine▲impact 4
Lilly's Jaypirca Wins FDA Approval as First-Line CLL/SLL Treatment
Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved an expanded indication for Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion, allowing use as a first-line therapy. The approval is based on the primary analysis of the Phase 3 BRUIN CLL-313 trial, the first prospective, randomized Phase 3 study to examine a non-covalent BTK inhibitor in previously untreated CLL/SLL without 17p deletion, which enrolled 282 patients randomized 1:1 to pirtobrutinib or bendamustine plus rituximab. At a median follow-up of 28 months, Independent Review Committee-assessed progression-free survival was significantly improved with pirtobrutinib versus bendamustine plus rituximab (HR=0.20 [95% CI, 0.11–0.37]; p<0.0001), with median PFS not yet reached for pirtobrutinib compared to 33.5 months for bendamustine plus rituximab, while IRC-assessed overall response rate was 94% (95% CI, 89–98) for pirtobrutinib versus 81% (95% CI, 73–87) for the comparator. In the trial, adverse reactions led to dose reductions in 3.6% and permanent discontinuation of Jaypirca in 4.3% of patients, with serious adverse reactions in 28% of those receiving the drug. Jaypirca is the first-and-only non-covalent BTK inhibitor recommended by the National Comprehensive Cancer Network, holding a Category 2A recommendation for treatment-naïve adult CLL/SLL patients without del(17p) and a Category 1 preferred option for relapsed or refractory patients previously treated with a covalent BTK inhibitor.
Foghorn Therapeutics Ends Eli Lilly Collaboration, Cuts 40% of Workforce
Foghorn Therapeutics and Eli Lilly will not advance their FHD-909 program into clinical development expansion following a review of Phase 1 data, and will also halt their Selective SMARCA2 degrader program with no further collaboration activities expected. Foghorn will instead prioritize its wholly owned pipeline, including a Selective EP300 degrader, an oral immunology and inflammation program, a Selective CBP degrader, and its induced proximity platform. The pipeline reprioritization and organizational changes, including an approximately 40% workforce reduction, are expected to extend Foghorn's cash runway into the second half of 2029; the company had $167.6 million as of June 30, 2026. Preclinical data for the EP300 degrader showed superior anti-tumor activity with complete responses compared to the clinical benchmark dual CBP/EP300 inhibitor inobrodib, along with safety in body weight loss and platelet counts and tumor regression in a multiple myeloma xenograft model of acquired pomalidomide resistance. Foghorn is targeting an FDA Investigational New Drug application for human trials in 2027, focused on multiple myeloma and diffuse large B-cell lymphoma. FHTX shares were down 27.17% at $2.60 on Thursday, trading at a new 52-week low.
Biotech & Genomic Medicine › Oncology Therapeutics Technology
FHTX · Capital · Negative Foghorn ends its Eli Lilly collaboration on FHD-909 and SMARCA2 programs and cuts 40% of its workforce, a major setback to its pipeline and finances.
LLY · Capital · Neutral Eli Lilly halts collaboration activities with Foghorn on FHD-909 and the SMARCA2 degrader, a minor pipeline pruning for the large-cap.
Eli Lilly's Positive Earnings ESP Points to Another Beat on October 29, 2026
Eli Lilly is positioned to potentially beat earnings estimates again when it reports on October 29, 2026, according to Zacks Investment Research. The drugmaker has topped estimates by 30.27% on average over the last two quarters, reporting $8.38 per share against a $6.01 consensus in the most recent quarter, a surprise of 39.43%, and $8.55 per share against a $7.06 consensus in the prior quarter, a surprise of 21.10%. Lilly currently carries a Zacks Earnings ESP of +0.64% alongside a Zacks Rank #3 (Hold), a combination that Zacks research shows produces a positive surprise nearly 70% of the time. The Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, capturing analyst revisions made just before an earnings release.
Novo's Oral Obesity Drug Wegovy, Patients Continue Losing Weight After Switching From Injections
Clinical trial data has revealed that patients who switched from weight-loss injections to Novo Nordisk's once-daily oral obesity treatment Wegovy continued to lose weight. The findings were presented at the European Association for the Study of Diabetes meeting held on the 30th in Milan, Italy. The 194 people who took part in the study switched from injectable obesity drugs, including Wegovy and Eli Lilly's Zepbound, to oral semaglutide, the active ingredient in Wegovy and Novo Nordisk's diabetes drug Ozempic, and recorded an average weight loss of 4.1 percent over three months. After switching, patients lost an average of 4.0 kilograms from a baseline weight of 100.5 kilograms, and the proportion of participants classified as clinically obese fell from 87.1 percent to 65.5 percent after three months, with nearly 41 percent achieving at least a 5 percent weight reduction. Novo Nordisk launched the injectable form of Wegovy in 2021 and rose to become Europe's most valuable listed company, but as Eli Lilly overtakes it as the leader in the obesity drug market, its share price has fallen more than 70 percent from its peak. According to an announcement the company made this month, since the launch of the tablet, oral drugs now account for about one-third of obesity treatment prescriptions in the United States, and the company has captured more than 80 percent of new oral drug prescriptions.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
NVO · Technology · Positive Trial data showed patients switching to once-daily oral Wegovy (oral semaglutide) continued losing weight, supporting its oral obesity treatment.
NVO · Demand · Positive Company said oral drugs now account for about one-third of US obesity prescriptions and it captured over 80% of new oral prescriptions.
LLY · Competition · Neutral Zepbound is named only as an injectable drug patients switched away from, and Eli Lilly is noted as overtaking Novo in the obesity market — context, not a new Lilly development.
Lilly's oral GLP-1 Foundayo cuts cardiovascular risk in largest type 2 diabetes trial
Eli Lilly and Company said its oral GLP-1 pill Foundayo, or orforglipron, met the primary objective of its Phase 3 ACHIEVE-4 trial, showing a non-inferior risk of major adverse cardiovascular events versus titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. In the study, the largest and longest trial of the medicine in type 2 diabetes to date, the risk of MACE-4 was 16% lower for Foundayo than insulin glargine, with a hazard ratio of 0.84, and the risk of MACE-3 was 23% lower, with a hazard ratio of 0.77. Pre-planned analyses showed a 53% lower risk of cardiovascular death and a 57% lower risk of all-cause death versus insulin glargine. At 52 weeks, Foundayo reduced A1C by 1.6% from a mean baseline of 8.22%, compared with 1.0% for insulin glargine, and cut body weight by 8.8% from a mean baseline of 90.9 kg, or 200.4 lbs, while insulin glargine patients gained 1.7%. The trial randomized 2,749 participants across 16 countries, and the results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy, and simultaneously published in The Lancet. Lilly is also conducting ATTAIN-OUTCOMES, an ongoing Phase 3 study of Foundayo in adults with established cardiovascular or kidney disease.
Novo's Ozempic Cuts Cardiovascular Risk More Than Lilly's Mounjaro in Real-World Study
Novo Nordisk said new real-world data from its COMPETE SWITCH Cardiovascular study found that type II diabetes patients who increased their Ozempic dose had a lower observed risk of major adverse cardiovascular events than those who switched to Eli Lilly's Mounjaro. In the study, 67.2% of patients remained on Ozempic 1 mg within 365 days, 29.2% increased their dose to 2 mg and 3.6% switched to Mounjaro; by 720 days, 57.4% remained on semaglutide 1 mg, 36.9% had escalated to 2 mg and 5.7% had switched to Mounjaro. After adjustment for between-group differences, patients who increased their dose to Ozempic 2 mg had a statistically significant 6% lower risk of MACE than those who switched to Mounjaro, including doses of up to 15 mg, with MACE defined as all-cause death, heart attack and stroke. Novo cautioned that the study showed an association, not proof, that Ozempic 2 mg directly reduces cardiovascular risk more than Mounjaro, and that safety outcomes were not evaluated. Year to date, Novo shares have lost 22.2% against the industry's 14.9% growth.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
NVO · Technology · Positive Novo's own COMPETE SWITCH study found escalating to Ozempic 2 mg was associated with a statistically significant 6% lower MACE risk than switching to Mounjaro.
LLY · Competition · Negative Real-world COMPETE SWITCH data show patients on Ozempic 2 mg had a 6% lower MACE risk than those who switched to Lilly's Mounjaro, a competitive blow to Mounjaro.
Eli Lilly's EloraTZP Combo Cuts 23.3% of Weight in Phase 2b Trial
Eli Lilly reported that its experimental obesity and type 2 diabetes combination EloraTZP delivered up to 23.3% average weight loss in a Phase 2b trial, sending its shares up as much as 2.6% before closing 0.5% higher. In the 48-week trial of 367 participants, the combination of eloralintide and tirzepatide produced average weight loss of up to 54.1 lbs, or 23.3%, far outpacing the 34.4 lbs, or 14.8%, achieved by a 15 mg dose of tirzepatide alone. EloraTZP also reduced A1C levels by an average of up to 2.9%, compared with 2.4% for tirzepatide, and met all primary and secondary endpoints across the tested dose combinations, with the highest dose of 9 mg eloralintide plus 15 mg tirzepatide yielding the greatest reductions. The triple-hormone therapy activates GIP, GLP-1 and amylin; gastrointestinal side effects were the most common, and discontinuation rates for EloraTZP ranged from 10.8% to 27.0%, versus 2.9% for tirzepatide alone and 16.7% for placebo. Following the results, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy, Eli Lilly plans to begin Phase 3 trials of EloraTZP in the fourth quarter of 2026, while shares of rival Novo Nordisk slipped 0.3%.
Novo Licenses Hengrui's Oral GLP-1 Candidate HRS-1596 in Deal Worth Up to $2.6 Billion
Novo Nordisk has signed a licensing agreement with Hengrui Pharma for HRS-1596, a phase I-ready GLP-1/GIP dual receptor agonist with potential for once-weekly oral dosing. Under the deal, Novo gains exclusive rights to develop, manufacture and commercialize the candidate globally outside mainland China, Hong Kong, Macao and Taiwan, with a total potential value of up to $2.6 billion including a $300 million upfront payment plus potential sales royalties; Hengrui has received approval in China to begin phase I studies of HRS-1596 for weight management and type II diabetes, and the transaction is expected to close in the fourth quarter subject to regulatory and customary conditions. The agreement builds on Novo's February partnership with Vivtex, under which Vivtex licensed selected oral drug-delivery technologies to Novo and is eligible for up to $2.1 billion in upfront consideration, research funding and milestone payments plus royalties, and on last year's exclusive global collaboration with Septerna, which received a $195 million upfront payment under an agreement providing for approximately $2.2 billion across upfront, research, development and commercial milestone payments plus tiered royalties. Novo is pursuing this external innovation strategy because semaglutide-based products, comprising Ozempic and Rybelsus for T2D and Wegovy for obesity, generated roughly 75.5% of its adjusted first-half 2026 sales, leaving it heavily exposed to competition and exclusivity shifts. Rival Eli Lilly's tirzepatide-based Mounjaro generated $18.6 billion in first-half 2026 sales, up 106%, while Zepbound sales rose 60% to $9.1 billion, and Lilly's oral obesity treatment Foundayo launched in the United States in April and is under regulatory review in more than 40 additional countries. Novo's first-half Ozempic sales declined 2% at constant exchange rates while Wegovy product sales increased 7%, and its latest outlook calls for both adjusted sales and adjusted operating profit to decline 0% to 6% at constant exchange rates in 2026.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
600276.CG · Capital · Positive Hengrui licenses HRS-1596 to Novo for up to $2.6B including a $300M upfront payment plus royalties.
NVO · Capital · Positive Novo gains global rights to Hengrui's oral GLP-1/GIP candidate HRS-1596 for up to $2.6B, expanding its pipeline beyond semaglutide.
LLY · Competition · Negative Novo's licensing of an oral GLP-1/GIP candidate strengthens a rival in the obesity/diabetes market where Lilly's tirzepatide and oral Foundayo compete.
Lilly's EBGLYSS Meets Endpoints in Phase 3b Hand and Foot Eczema Trial
Eli Lilly and Company said its drug EBGLYSS, also known as lebrikizumab-lbkz, met its primary and secondary endpoints at Week 16 in the Phase 3b ADtouch study of adults and adolescents with moderate-to-severe hand and foot atopic dermatitis. In the trial, 53% of patients on EBGLYSS monotherapy achieved clear or almost clear skin on their hands and feet, measured as HF-IGA 0/1 with at least a 2-point improvement, versus 27% on placebo, with significant skin clearance seen as early as Week 4 at 17% versus 6%. Itch relief was also rapid, with 57% of EBGLYSS patients reaching at least a 4-point improvement on the HF-Peak Pruritus NRS at Week 16 versus 19% on placebo, and 16% versus 1% as early as Week 2. Pain improvement of at least 4 points on the HF-Peak Pain NRS was reported in 59% of EBGLYSS patients at Week 16 versus 19% on placebo, while in first-of-its-kind patient satisfaction data, 77% of EBGLYSS patients were satisfied or very satisfied with hand clearance at Week 16 versus 40% on placebo. Lilly has submitted the data to the U.S. Food and Drug Administration and plans to file with select global regulators for a potential label update covering localized atopic dermatitis with moderate-to-severe hand and foot involvement, with the late-breaking results presented at the European Academy of Dermatology and Venereology Congress in Vienna.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Technology
LLY · Technology · Positive EBGLYSS met primary and secondary endpoints in the Phase 3b ADtouch hand and foot eczema trial, supporting a potential label update.
Eli Lilly Shares Rise After Foundayo Shows More Weight Loss
Eli Lilly shares edged 1% higher in morning trading Tuesday after new data showed its oral Foundayo treatment produced greater weight and blood-sugar reductions than oral semaglutide at higher doses. The analysis examined 17.2 mg of Foundayo, or orforglipron, in adults with type 2 diabetes, and at week 52 patients receiving the Lilly drug recorded 1.5% more body-weight reduction than those taking 25 mg of oral semaglutide. The blood-sugar measure A1C also moved in Lilly's favor, with the analysis showing a further 0.3% reduction compared with the semaglutide group. The findings were presented during the European Association for the Study of Diabetes meeting in Milan, where EASD materials listed additional studies involving the treatment. Lilly has been developing Foundayo across its diabetes program as competition in oral GLP-1 medicines expands, though the comparison comes from separate studies rather than a direct head-to-head trial.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Aging Population › Chronic-Disease Pharma Franchises ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Competition
LLY · Technology · Positive New data showed Lilly's oral Foundayo produced greater weight and blood-sugar reductions than oral semaglutide at higher doses.
Lilly Says Higher-Dose Zepbound Widened Weight-Loss Lead Over Wegovy
Eli Lilly says higher doses of Zepbound may have widened its weight-loss advantage over Novo Nordisk's Wegovy. A new indirect analysis found that patients receiving Zepbound 15 mg and 10 mg had 4.5 percentage points and 3.2 percentage points more weight loss, respectively, over 72 weeks than patients taking high-dose Wegovy. According to Lilly, patients receiving Zepbound 15 mg were three times more likely to lose at least 20% of their body weight compared with those receiving Wegovy HD, and the difference was even more pronounced among people reaching larger weight-loss goals. Discontinuation rates because of adverse events were comparable across the Zepbound 10 mg, Zepbound 15 mg and Wegovy HD groups. Lilly cautioned that the results did not come from a direct head-to-head trial, comparing data from its Phase 3 SURMOUNT-1 study with Novo Nordisk's STEP UP studies. Novo shares were down about 1.3% in Tuesday premarket trading, while Lilly was up roughly 0.4%.
Lilly Says Higher-Dose Zepbound Tops Novo's Wegovy HD on Weight Loss
Eli Lilly announced Tuesday that higher doses of its obesity therapy Zepbound produced greater weight loss than Wegovy HD, the high-dose version of Novo Nordisk's rival GLP-1 therapy semaglutide. Citing a new indirect comparison, the U.S. drugmaker said Zepbound 10 mg and 15 mg generated higher body weight reductions over 72 weeks than Wegovy HD. Patients on Zepbound 15 mg and 10 mg recorded 4.5% and 3.2% additional body weight on average, respectively, and those receiving Zepbound 15 mg were three times more likely to achieve 20% or higher weight reduction compared with those on Wegovy HD. Lilly presented the data at the annual meeting of the European Association for the Study of Diabetes and added that discontinuation rates due to adverse events were comparable across Zepbound 15 mg, Zepbound 10 mg, and Wegovy HD. The analysis drew on data from Lilly's SURMOUNT-1 trial and Novo's STEP UP studies, Phase 3 trials that enrolled thousands of obese or overweight adults globally to evaluate 5 mg, 10 mg, and 15 mg of tirzepatide and Wegovy HD, respectively, in support of regulatory submissions for the GLP-1s.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▼Competition
LLY · Technology · Positive Lilly's higher-dose Zepbound showed greater weight loss than Novo's Wegovy HD in an indirect comparison, strengthening its obesity-therapy profile.
NVO · Competition · Negative Novo's Wegovy HD was shown to produce less weight loss than Zepbound in the head-to-head indirect comparison, a competitive setback.
Eli Lilly Wins FDA Breakthrough Status for Pancreatic Cancer Drug
Eli Lilly received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer. The designation flags olomorasib as a priority asset in KRAS driven pancreatic cancer, an area with high medical need and limited options, and reinforces Lilly's push to balance its incretin heavy portfolio with oncology drugs targeting defined mutations. The pharmaceutical group also launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments in low and middle income countries. CEO Dave Ricks signaled a shift toward larger acquisitions in new therapeutic areas that extend beyond the firm's current obesity focus, with the clearest marker being the size and stage of the next acquisition relative to the US$7.8b Centessa purchase, especially if it lands in areas like infectious disease, women's health, or psychiatry.
Eli Lilly Wins FDA Approval for Once-Weekly Onswik and Expanded Alopecia Label
Eli Lilly has secured U.S. FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, and won an expanded label for Olumiant to treat adolescents 12 and older with severe alopecia areata. Both approvals were supported by large Phase 3 programs showing efficacy and consistent safety profiles. The Onswik clearance adds another branded option alongside Mounjaro and Foundayo, reinforcing Lilly's push to build an integrated cardiometabolic platform rather than a single-product bet. Lilly is also broadening its pipeline and commercial reach through research collaborations, manufacturing expansion and AI-enabled discovery efforts, aiming to diversify beyond its core obesity and diabetes franchises. The company's narrative projects $118.6 billion in revenue and $49.8 billion in earnings by 2029, requiring 14.2% yearly revenue growth and a $23.1 billion earnings increase from $26.7 billion today.
Roche Obesity Drug Enicepatide Cuts Blood Sugar, 15.5% Weight in Mid-Stage Trial
Roche's experimental obesity drug enicepatide helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial, adding another potentially important asset to the company's effort to challenge obesity-market leaders Eli Lilly and Company and Novo Nordisk A/S. In the 447-patient study, patients receiving the highest 24-milligram dose experienced significant reductions in HbA1c at 48 weeks, meeting the study's two main goals, and Roche said approximately 62% of patients achieved HbA1c levels below 5.7%, putting their blood sugar into the non-diabetic range. The findings follow a separate mid-stage result reported in June in which enicepatide helped overweight or obese patients without diabetes lose 22.7% of their body weight; Roche said the two weight-loss figures should not be directly compared because they come from separate trials involving different patient populations. Roche plans to begin late-stage glycemic-control and cardiovascular-outcomes studies during the first half of 2027, though enicepatide remains an experimental drug and the latest results should not be treated as evidence of regulatory approval or eventual commercial success. Roche said around 2% of patients taking enicepatide in the 447-patient study discontinued treatment because of side effects, compared with none in the placebo group, with most gastrointestinal side effects described as mild to moderate, and the company is betting on next-generation therapies in an obesity market expected to exceed $100 billion in annual sales within the next decade, where AstraZeneca and Amgen are among the large drugmakers also racing to break in.
Lilly CEO Signals Bigger Deals in Hunt for Pharma's 'White Spaces'
Eli Lilly & Co. will pursue slightly larger acquisitions, along the lines of its $7.8 billion purchase of Centessa Pharmaceuticals Plc, as it searches for assets in the "white spaces" of science, Chief Executive Officer Dave Ricks said. Lilly, now the world's largest pharmaceutical company, has been on a record spending spree funded by its weight-loss and diabetes shots, and Ricks told Bloomberg that reinvesting in human health is more attractive than buying back shares or issuing dividends. He pointed to infectious disease, women's health and psychiatric conditions as areas of opportunity, noting the company acquired three vaccine-makers for as much as $3.8 billion earlier this year and recently agreed to buy psychedelics firm AtaiBeckley Inc. for about the same price. Lilly has completed about 40 deals so far this year, with a total value of more than $20 billion, the highest ever in a single year according to Bloomberg-compiled data. Ricks said the company favors more mature assets when they address brand new problems, a shift from its historical focus on earlier-stage, cheaper drugs.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Capital
Psychedelic Medicine › Psilocybin Therapeutics ▲Capital
Psychedelic Medicine › Novel Psychedelic & Next-Gen Pipeline ▲Capital
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) ▲Capital
Biotech & Genomic Medicine › Antiviral & Infectious-Disease Therapeutics ▲Capital
Psychedelic Medicine › MDMA-Assisted Therapy ▲Capital
LLY · Capital · Positive CEO Dave Ricks signaled Lilly will pursue larger acquisitions funded by its weight-loss/diabetes cash flow, with ~40 deals worth over $20 billion this year.
Centessa Pharmaceuticals · Capital · Positive Lilly's $7.8 billion purchase of Centessa Pharmaceuticals is cited as the template for its larger deal strategy.
ATAI · Capital · Positive Lilly agreed to acquire psychedelics firm AtaiBeckley (ATAI Life Sciences) for about $3.8 billion, a buyout premium for the company.
Eli Lilly's Olumiant Wins FDA Approval for Adolescent Severe Alopecia Areata
Eli Lilly and Company announced that the FDA has approved Olumiant, a once-daily oral therapy, for pediatric patients 12 years of age and older with severe alopecia areata, expanding the drug's U.S. label to include adolescents with severe hair loss. The approval was supported by 36-week results from the ongoing phase III BRAVE-AA-PEDS study, in which 42% of patients receiving Olumiant 4 mg and 27% receiving the 2-mg dose achieved a SALT score of 20 or less at week 36, corresponding to at least 80% scalp hair coverage, compared with 5% for placebo. At the same 36-week mark, 37% of patients on Olumiant 4 mg reached a SALT score of 10 or less, representing at least 90% scalp hair coverage, versus 21% for the 2-mg dose and 2% for placebo. The drug is already approved in several geographies for adults with moderately to severely active rheumatoid arthritis and adults with severe alopecia areata, and in April 2026 the European Commission approved Olumiant for adolescents aged 12 to under 18 with severe alopecia areata. Olumiant, a once-daily oral JAK inhibitor discovered by Incyte and licensed to Lilly, is also approved in the United States to treat hospitalized adults with COVID-19, and per Eli Lilly more than 33,000 patients have been prescribed it in the United States since 2017.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Regulation
LLY · Regulation · Positive FDA approves Eli Lilly's Olumiant for pediatric patients 12+ with severe alopecia areata, expanding its U.S. label.
INCY · Regulation · Positive Olumiant, discovered by Incyte and licensed to Lilly, wins FDA approval for adolescent severe alopecia areata, expanding the drug's label.
Lilly Launches Change the Course Commitment to Close Diabetes and Obesity Access Gap in LMICs by 2040
Eli Lilly and Company launched the Lilly Change the Course Commitment, a global health initiative aiming to achieve parity in the number of patients treated with its innovative diabetes and obesity medicines in resource-limited settings, including low- and middle-income countries, compared with high-income countries before 2040. Today, for every 4 people in high-income countries who have access to Lilly's diabetes and obesity medicines, only 1 person in low- and middle-income countries can reach them. The commitment is organized around three pillars: developing medicines suitable for people in resource-limited settings from the earliest stages of clinical development, registering and expanding access to medicines including GLP-1s with a focus on Africa, Latin America and Asia, and helping strengthen health systems through community health worker training and digital tools. The announcement follows the completion of the Lilly 30x30 global health initiative five years ahead of schedule, which expanded access to quality healthcare for 40 million people in resource-limited settings in 2025, exceeding its original goal of reaching 30 million people annually by 2030. Lilly chair and CEO David A. Ricks said innovative medicines like Foundayo, or orforglipron, an oral treatment that can be stored at room temperature, will help the company distribute and scale access across more LMICs. Lilly will report progress in treatment reach through its annual Sustainability Report and at key global health forums.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
LLY · Demand · Positive Lilly launches Change the Course Commitment to expand access to its diabetes and obesity medicines, including GLP-1s, across low- and middle-income countries by 2040, broadening its patient base.
Novo Nordisk Lifts 2026 Guidance as Lilly's Zepbound Pulls Ahead
Novo Nordisk raised its 2026 sales and operating-profit growth outlook to a range of 0% to negative 6% at constant exchange rates, up from a prior negative 4% to negative 12%. The Danish drugmaker faces renewed investor pressure over what comes after its weight-loss franchise, with analysts projecting Eli Lilly's Zepbound will outsell Novo's Wegovy by more than $7 billion this year. CEO Mike Doustdar has cut costs, ended weak programs, and pursued targeted acquisitions and partnerships, while Novo has five oral candidates in development and expects pills could capture as much as half of the obesity market by 2030. The company halted trials of heart drug ziltivekimab and CagriSema disappointed investors, and semaglutide already faces generic competition in markets including India, Canada, and Brazil after 2026 patent expiries, even though protection in major Western markets holds into the early 2030s. Hedge fund holdings in Novo rose to 59 funds with $2.00 billion in position value in the second quarter of 2026 from 55 funds and $1.79 billion in the first, while Eli Lilly's holders rose to 152 from 132 and position value jumped to $17.24 billion from $12.58 billion.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
Biotech & Genomic Medicine › Cardiovascular & Heart-Failure Therapeutics ▼Technology
NVO · Capital · Neutral Novo Nordisk raised its 2026 sales and operating-profit growth outlook to 0% to negative 6% from negative 4% to negative 12%.
NVO · Competition · Negative Eli Lilly's Zepbound is projected to outsell Novo's Wegovy by more than $7 billion this year, and CagriSema disappointed investors.
LLY · Competition · Positive Analysts project Eli Lilly's Zepbound will outsell Novo's Wegovy by more than $7 billion this year, and Lilly's hedge-fund position value jumped to $17.24 billion.
Lilly Captures 70% of 700,000 New Medicare GLP-1 Patients
Eli Lilly CEO David Ricks said about 700,000 new seniors have started GLP-1 treatment since Medicare began covering obesity drugs in July, with roughly 70% using Lilly medicines. The temporary Medicare Bridge program lets eligible beneficiaries obtain obesity treatments for a $50 monthly co-pay, giving Zepbound and Foundayo access to a population that previously faced limited Medicare coverage. The early uptake matters because Zepbound generated $9.09 billion in revenue in the first half of 2026, up 60% year over year, while Mounjaro generated $18.61 billion, up 106%, with the two drugs together representing 65% of Lilly's total revenue in the period. Ricks said Zepbound remains popular among patients with higher body weight and more complications, while one-third of new oral GLP-1 patients are taking Foundayo, which Reuters reported had captured more than 30% of new U.S. oral obesity-drug patients. Medicare's Bridge program also covers Novo Nordisk's Wegovy and runs through December 2027, and Lilly has said higher volumes of Mounjaro and Zepbound have come with lower realized prices.
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
LLY · Demand · Positive Medicare Bridge coverage drove ~700,000 new seniors to GLP-1s, with roughly 70% using Lilly medicines like Zepbound and Foundayo
NVO · Demand · Neutral Medicare Bridge program also covers Novo Nordisk's Wegovy, but the article gives no specific uptake figures for Novo
Novo Nordisk Slides 7% on Patent Fears as Lilly Wins FDA Nod for Weekly Insulin
Novo Nordisk shares fell as much as 7% after its Capital Markets Day in London, even as the Wegovy-maker set a $23B obesity sales target and 2030 growth goals. CEO Mike Doustdar told investors the "elephant in the room" was that semaglutide, the active ingredient in Wegovy and Ozempic, loses key patent exclusivity starting in the early next decade, expiring in 2032 in the U.S., which accounts for more than half of its sales. In a separate development, Eli Lilly won U.S. FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, which the company says could cut more than 300 insulin injections annually compared with once-daily basal insulin; Lilly expects to launch it in the coming months in 500 units/mL and 1,000 units/mL concentrations. InnoCare Pharma signed a research collaboration and license agreement with Eli Lilly worth up to $3.35B, comprising up to $100M in upfront and near-term payments and up to $3.25B in milestone-based payments, plus single-digit tiered royalties. The Trump administration also announced it will remove hundreds of thousands of people from Affordable Care Act exchanges over fraud allegations, ending subsidy payments for 750,000 individual accounts, while the CMS said it canceled about 315,000 ACA enrollments on August 31, affecting more than 760,000 individuals and generating a $2.2B gain in advance premium tax credit payments.
Guggenheim Lifts Lilly Price Target and Raises Foundayo Revenue Forecasts
Guggenheim raised its price target on Eli Lilly and Company to $1,284 from $1,273 while keeping a Buy rating, but the bigger change was a sharp upward revision to its revenue forecasts for Lilly's oral obesity drug Foundayo. The firm now expects Foundayo to generate $1.8 billion in revenue in 2027 and $3.7 billion in 2028, up from previous estimates of $1.2 billion and $2.4 billion, respectively, while maintaining its 2026 estimate even as it modeled a lower price for the 2.5-mg dose for the remainder of the year. The revision follows improving prescription trends: IQVIA data show Foundayo prescriptions rose nearly 8% to about 47,500 in the reporting week through September 11, and Lilly said on September 14 that the drug had captured more than 30% of new U.S. patients in the oral obesity-treatment market, narrowing the early lead held by rival Novo Nordisk's Wegovy pill. Access has also improved, with CVS Caremark beginning coverage of Foundayo on June 1 and its coverage of Zepbound scheduled to resume October 1, which Lilly said means all three of the largest US pharmacy benefit managers will cover its full obesity medicine portfolio. Lilly raised its 2026 revenue guidance to $85 billion - $87 billion from $82 billion - $85 billion after strong Q2 revenue growth supported by a 60% increase in worldwide volume that was partly offset by a 13% decline in realized prices, underscoring the need for prescription growth to outpace pricing pressure.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
LLY · Capital · Positive Guggenheim raised its Lilly price target to $1,284 and sharply lifted Foundayo revenue forecasts for 2027-2028.
LLY · Demand · Positive Foundayo prescriptions rose ~8% to ~47,500 and the drug captured over 30% of new U.S. oral obesity patients, with Lilly raising 2026 revenue guidance on 60% volume growth.
NVO · Competition · Negative Lilly's Foundayo is narrowing the early lead held by Novo Nordisk's Wegovy pill in the oral obesity market.
CVS · Demand · Positive CVS Caremark began covering Foundayo on June 1 and will resume Zepbound coverage Oct 1, expanding access to Lilly's obesity drugs.
Jury Awards Nektar Therapeutics $90 Million in Eli Lilly Licensing Dispute
A federal jury in California has awarded Nektar Therapeutics $90 million in damages after finding that Eli Lilly breached the implied covenant of good faith and fair dealing. The lawsuit, filed in August 2023, stemmed from a prior licensing agreement between the two companies covering development and commercialization of the drug rezpegaldesleukin. The trial in the U.S. District Court for the Northern District of California began on September 8, and the jury delivered its verdict on September 24. Beyond the $90 million in damages, the court will determine the amount of interest to be added to the award, and the decision remains subject to post-trial proceedings and possible appeal. Separately, Nektar in July 2026 initiated the first two global registrational trials in the Phase 3 ZENITH AD program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis, part of a three-study program that also includes ZENITH AD-3.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Competition
LLY · Regulation · Negative Jury found Eli Lilly breached the implied covenant of good faith and fair dealing in the Nektar licensing deal, awarding $90 million in damages.
NKTR · Regulation · Positive Nektar won a $90 million jury award against Eli Lilly over the rezpegaldesleukin licensing agreement.
NKTR · Technology · Positive Nektar initiated the first two global registrational Phase 3 ZENITH AD trials of rezpegaldesleukin in atopic dermatitis.
FDA Approves Eli Lilly's Once-Weekly Insulin Onswik for Type 2 Diabetes
The U.S. Food and Drug Administration approved Eli Lilly's once-weekly basal insulin Onswik for adults with type 2 diabetes, sending shares of the global pharmaceutical company up 3.1% in the afternoon session. Lilly said Onswik, chemically known as insulin efsitora alfa-gobe, is intended for use with diet and exercise to control high blood sugar and could cut injections by more than 300 per year compared with once-daily basal insulin. The drug will be available in the U.S. in the coming months as a pre-filled KwikPen in 500 units/mL and 1,000 units/mL concentrations. Approval was based on late-stage trials enrolling more than 3,400 adults across four studies in which Onswik met its main goal by showing A1C reductions not inferior to daily basal insulin glargine, and the therapy should not be used in type 1 diabetes because of a higher risk of severe hypoglycemia. Onswik was already approved in Europe, Japan, and Mexico, and the once-weekly option strengthens Lilly's diabetes franchise as it competes with rivals such as Novo Nordisk in basal insulin. The shares were trading at $1,192, up 3.4% from the previous close.
InnoCare Signs Licensing Deal With Eli Lilly Worth Up to $3.35B
InnoCare Pharma has entered a research collaboration and license agreement with Eli Lilly to develop new medicines, the companies said on Thursday. Under the deal, InnoCare will use its drug discovery platform and research to discover and advance compounds against up to five targets. InnoCare is eligible to receive up to $100M in upfront and near-term payments, plus milestone-based payments of up to $3.25B contingent on development and commercial achievements. The company will also be eligible for single-digit tiered royalties based on annual net product sales.
Biotech & Genomic Medicine › AI Drug Discovery Competition
688428.CG · Capital · Positive InnoCare signs licensing deal with Eli Lilly worth up to $3.35B, including up to $100M upfront and $3.25B in milestones plus royalties.
LLY · Capital · Positive Eli Lilly signs licensing deal with InnoCare worth up to $3.35B to develop new medicines against up to five targets.
Lilly Breaks Ground on $6.5 Billion Houston Plant for Oral GLP-1 Pill
Eli Lilly broke ground on a $6.5 billion Houston plant built to make ingredients for its Foundayo weight-loss pill and other medicines, with shares slipping about 0.8% to $1,160.91 Wednesday morning. The Houston site accounts for 13% of Lilly's $50 billion U.S. manufacturing push and is expected to create more than 600 permanent jobs and about 4,000 construction jobs. Foundayo is already on the U.S. market, while regulators in more than 40 other countries are reviewing it ahead of Lilly's targeted 2027 global rollout. Reuters reported that Lilly has captured more than 30% of new U.S. patients starting oral obesity treatment, though overseas approvals, coverage and sustained sales will decide whether the plant turns that early demand into a strong return.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Supply
LLY · Capital · Positive Lilly breaks ground on a $6.5 billion Houston plant, part of its $50 billion U.S. manufacturing push, expanding capacity for its Foundayo obesity pill.
Novo Nordisk Wins CHMP Backing for Frehemgo and Sogroya in Rare Disease Push
Novo Nordisk announced two European regulatory advances for its Rare Disease portfolio, with the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of denecimig, to be marketed as Frehemgo, for hemophilia A in adults and children with or without inhibitors, and issuing a positive opinion for once-weekly Sogroya, or somapacitan, in children with idiopathic short stature or unexplained shortness. Both decisions still require final European Commission action. Novo expects to launch Frehemgo in the first European countries in the fourth quarter of 2026, followed by broader EU availability in early 2027, and denecimig is also under FDA review for the same hemophilia A indication. The Sogroya opinion follows a May 2026 CHMP recommendation for children with short stature born small for gestational age and those with Noonan syndrome, and the pending EC decision will cover all three indications; if approved, Sogroya would become the first and only growth hormone treatment authorized for idiopathic short stature in the EU. Novo generated DKK 9.1 billion in adjusted Rare Disease sales in the first half of 2026, and the segment also includes Alhemo, approved in the United States, Europe, Japan and Australia for routine prophylaxis in patients aged 12 years and older with hemophilia A or B, plus etavopivat, which has completed phase III development in sickle cell disease and phase II development in thalassemia. The Rare Disease push comes as Novo's core GLP-1 franchise faces intensifying competition, with Eli Lilly's Mounjaro generating $18.6 billion in first-half 2026 sales, up 106% year over year, and Zepbound sales rising 60% to $9.1 billion, while Novo's first-half Ozempic sales declined 2% at constant exchange rates and Wegovy product sales increased 7%.
Biotech & Genomic Medicine › Rare Disease ▲Regulation
Biotech & Genomic Medicine › Plasma-Derived & Blood Products Competition
NVO · Regulation · Positive CHMP recommended approval of Frehemgo (denecimig) for hemophilia A and issued a positive opinion for Sogroya in idiopathic short stature, advancing Novo's Rare Disease portfolio.
LLY · Competition · Negative Eli Lilly's Mounjaro and Zepbound are cited as intensifying competition against Novo's GLP-1 franchise, with Mounjaro sales up 106%.
Novo Nordisk Shares Fall 7.7% as Long-Term Targets Disappoint Investors
Novo Nordisk shares closed 7.7% lower on Monday, their worst day since February, after the Danish drugmaker unveiled long-term pipeline growth targets that failed to convince investors it can defend its weight loss drug market against fast-growing rivals. At its Capital Markets Day in London, Novo said it plans to launch more than five drugs with "multi-blockbuster" potential by 2030 and targets over 150 billion Danish kroner, roughly $23 billion, in risk-adjusted pipeline sales by 2035. The company also said revenue growth between 2026 and 2030 should match big pharma peers including Eli Lilly, AstraZeneca, Amgen, Biogen, Merck, AbbVie, and Novartis. CEO Mike Doustdar addressed what he called the "elephant in the room," noting that semaglutide, the active ingredient in Wegovy and Ozempic, loses key patent protection in the U.S. starting in 2032, a market that made up more than half of Novo's total sales last year. Nordnet savings economist Per Hansen said investors had hoped for a project "miracle" that could turn the momentum around short term, adding that "for obvious reasons that miracle does not exist." Novo Nordisk stock had already fallen 27% over the past 12 months heading into Monday, while rival Eli Lilly's stock gained 52% over the same stretch.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▼Competition
NVO · Competition · Negative Long-term pipeline targets failed to convince investors it can defend its weight loss market against fast-growing rivals, and semaglutide loses key US patent protection in 2032.
LLY · Competition · Neutral Named as the fast-growing rival whose stock gained 52% while Novo struggles, but no company-specific development is reported.
Viking's VK2735 Monthly Dosing Preserves Up to 90% Weight Loss as Lilly Shares Rise
Viking Therapeutics reported that patients on its VK2735 obesity drug preserved as much as 97% of prior weight loss with biweekly injections and up to 90% with monthly dosing, compared with 61% for those switched to placebo. The randomized Phase 1 study followed roughly 180 adults after an initial weekly-treatment phase. Eli Lilly shares rose 0.8% to $1,174.37 Tuesday as investors weighed the competitive readout. Lilly's second-quarter revenue surged 48% to $23 billion, powered mainly by rising Mounjaro and Zepbound volumes, and its $1,174.37 share price sits 24.35% below its $1,550 GF Value estimate. Viking's less-frequent schedule is intriguing, but pivotal trials, regulatory clearance, manufacturing scale and payer access still separate promising data from a genuine threat.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
VKTX · Technology · Positive VK2735 preserved up to 97% of prior weight loss with biweekly and 90% with monthly dosing in a Phase 1 study, a promising clinical readout.
LLY · Demand · Positive Lilly's Q2 revenue surged 48% to $23B powered by rising Mounjaro and Zepbound volumes, and its shares rose as investors weighed Viking's competitive readout.
Novo Nordisk Explores Hair-Loss Market in Push Beyond GLP-1 Drugs
Novo Nordisk is exploring the hair-loss market as the Ozempic and Wegovy maker looks to diversify beyond its blockbuster GLP-1 drugs. Chief Scientific Officer Martin Lange said Novo could leverage its scientific expertise to move into hair loss, though the company has not decided whether to pursue the market first. The comments came as Novo outlined plans to find new growth areas beyond its weight-loss franchise, targeting more than five drugs with multi-blockbuster potential by 2030 and expecting more than $23 billion in risk-adjusted pipeline sales by 2035. The company also plans to pursue bolt-on deals and accelerate development of treatments for heart, liver and blood disorders, as Eli Lilly has taken share in the injectable GLP-1 market and Novo faces a longer-term patent cliff for semaglutide, the active ingredient in Ozempic and Wegovy. Pattern hair loss affects an estimated 50 million men and 30 million women in the U.S., and no new FDA-approved therapy for the condition has emerged since the 1990s, according to the report.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
Biotech & Genomic Medicine › Cardiovascular & Heart-Failure Therapeutics ▲Demand
NVO · Competition · Negative Eli Lilly has taken share in the injectable GLP-1 market, pressuring Novo's core franchise.
NVO · Technology · Neutral Novo is exploring hair-loss treatments and accelerating heart, liver and blood disorder programs to diversify beyond GLP-1 drugs.
LLY · Competition · Neutral Mentioned only as having taken share in the injectable GLP-1 market, prompting Novo's diversification push.
Nektar Therapeutics Falls 11% as Jury Deliberates in Eli Lilly Rezpeg Patent Dispute
Nektar Therapeutics shares sank 11% as a jury deliberated in its patent dispute with Eli Lilly over its Rezpeg drug. The jury in San Francisco federal court has been deliberating since Friday, and the trial started earlier this month. Court observers told Seeking Alpha on Tuesday that the stock may have dropped after the jury asked about low and no damage results in the dispute.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
NKTR · Regulation · Negative Nektar shares fell 11% as the jury deliberates in its Rezpeg patent dispute with Eli Lilly, with questions about low/no damages.
LLY · Regulation · Neutral Eli Lilly is the opposing party in the Rezpeg patent dispute; jury deliberation outcome is uncertain for Lilly.
Novo's CagriSema Beats Lilly's Zepbound in Phase III Weight-Loss Trial
Novo Nordisk reported top-line results from two phase III studies of once-weekly CagriSema, its investigational fixed-dose combination of cagrilintide and semaglutide, in obesity and type II diabetes. In the 68-week REIMAGINE 5 study, CagriSema 1.0 mg/1.0 mg produced an estimated average body-weight reduction of 12.4% at week 60 versus 9.1% for Eli Lilly's tirzepatide 5 mg, the active ingredient in Zepbound and Mounjaro, meeting the superiority criterion for weight loss, while HbA1c fell 1.71% versus 1.67%, meeting the prespecified non-inferiority criterion. In the separate REDEFINE 9 study, CagriSema 1.0 mg/1.0 mg generated 21% weight loss at week 68 compared with 2% for placebo, meeting the primary superiority endpoint, with greater improvements on supportive measures including systolic blood pressure, waist-to-height ratio and fasting lipid profile. Novo filed a new drug application with the FDA in December 2025 seeking approval of CagriSema for weight management, with a regulatory decision expected in the fourth quarter of 2026. The company cautioned that the weight-loss comparison should be viewed within the specific study design and doses studied rather than as a direct comparison with every approved tirzepatide regimen.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
NVO · Technology · Positive CagriSema met superiority endpoints in two phase III trials, showing greater weight loss than Lilly's tirzepatide and versus placebo
LLY · Competition · Negative Novo's CagriSema beat Lilly's tirzepatide (Zepbound/Mounjaro) on weight loss in the REIMAGINE 5 head-to-head trial
Viking Therapeutics Stock Jumps 26% on 22% Weight-Loss Data for VK2735
Viking Therapeutics shares surged 26% after the company released trial data showing its experimental obesity drug VK2735 produced 22% weight loss, with patients maintaining up to 97% of prior weight loss when switching from weekly injections to every-other-week dosing. The stock is the top trending ticker on Yahoo Finance. Viking has periodically been discussed as a potential acquisition target for larger companies. Separately, Roche released study results for its experimental obesity shot, which cut blood sugar and body weight in overweight type 2 diabetes patients, but Roche shares saw little gain. Eli Lilly broke ground on a six and a half billion dollar plant in Houston to manufacture orforglipron, its daily oral GLP-1 drug.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
VKTX · Technology · Positive VK2735 trial data showed 22% weight loss with up to 97% maintained on every-other-week dosing, a strong efficacy result for its obesity drug.
LLY · Capital · Positive Eli Lilly broke ground on a $6.5B Houston plant to manufacture its oral GLP-1 drug orforglipron, expanding capacity for a key obesity pipeline asset.
ROP.SW · Technology · Neutral Roche's experimental obesity shot cut blood sugar and body weight in overweight type 2 diabetes patients, but shares saw little gain.
Novo sets 2030 blockbuster and DKr150bn sales targets as shares fall 5%
Novo outlined a five-year commercial strategy at its Capital Markets Day on 21 September, headlined by an ambition to launch more than five multi-blockbusters by 2030 and deliver more than DKr150bn ($23bn) in sales, but shares in the Copenhagen-listed company dropped 5% at market open that day and have tumbled more than 70% since their mid-2024 peak. The plan is part of Novo's effort to show investors a roadmap beyond semaglutide, the injectable versions of which, branded Wegovy and Ozempic, generated around $7.8bn in global sales in Q2, while Eli Lilly's combined Zepbound and Mounjaro tirzepatide sales reached just shy of $15bn in the same quarter. On the same day, Novo's obesity pipeline was bolstered by a Phase III REIMAGINE 5 readout showing next-generation GLP-1 receptor agonist CagriSema delivered superior weight loss in overweight and obese adults against the lower dose of tirzepatide, an important win for a drug that had previously disappointed in trials. The 2030 ambition also includes more than five Phase III programmes in obesity and diabetes and more than five in other therapy areas, with Novo having spent $5.2bn to acquire MASH specialist Akero Therapeutics in October 2025, and scaling capacity for its oral Wegovy, approved in the US in December 2025, to serve 10 times the number of people with obesity taking the pill-based option within five years. Citi analysts said the Capital Markets Day offered little to change their cautious view, noting mid-single-digit topline growth ambition for 2026-30 in line with consensus and that management did not rule out a large transaction, while the stock was also hit by the disclosure that Novo shed 13,000 staff in the past year.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
NVO · Capital · Negative Shares fell 5% as Citi saw little to change its cautious view and Novo disclosed shedding 13,000 staff in the past year.
NVO · Technology · Positive Phase III REIMAGINE 5 showed CagriSema delivered superior weight loss versus lower-dose tirzepatide, a pipeline win for Novo.
Novo · Capital · Negative Novo shares dropped 5% after the Capital Markets Day and the disclosure of 13,000 staff cuts.
Novo · Technology · Positive Novo's obesity pipeline was bolstered by the CagriSema Phase III REIMAGINE 5 readout showing superior weight loss.
LLY · Competition · Neutral Eli Lilly is referenced only as the tirzepatide comparison (Zepbound/Mounjaro ~$15bn Q2 sales) and as the comparator in Novo's CagriSema Phase III win.
Novo Nordisk Partners with Anthropic to Embed Claude AI in Drug Discovery
Novo Nordisk has partnered with Anthropic to deploy Claude models and Claude Science across its research and development workflows, initially targeting specific scientific problems where AI can have the greatest impact, and will also use Anthropic's frontier models for AI-driven software development. Reuters reported that Novo already uses Claude to automate clinical-trial report generation, cutting patient-documentation timelines from months to minutes. The deal expands an AI strategy that already includes partnerships with OpenAI and Amazon Web Services, and comes as Novo works to strengthen its pipeline amid rising obesity-drug competition; its Q2 adjusted sales rose 7% at constant exchange rates to DKK 78.5 billion, while adjusted operating profit increased 11% to DKK 33.4 billion. Novo simultaneously recorded DKK 6.3 billion in non-cash impairments on pipeline assets, including DKK 4 billion related to monlunabant, underscoring the need to improve R&D productivity. The immediate financial impact remains uncertain, as the companies have not disclosed specific drug targets, development milestones, financial terms, or expected cost savings, and the arrangement begins with testing Claude in selected workflows. Novo also faces pressure from Eli Lilly in an obesity market Reuters said could exceed $100 billion annually by 2030, with Lilly's oral obesity drug having captured more than 30% of new U.S. oral-weight-loss patients by September while Novo's Wegovy pill held an estimated 90% share as of August.
Oura launched its initial public offering on Monday, aiming to raise up to $2.2 billion by selling 50 million shares at a price range of $40 to $44 apiece. Of those 50 million shares, Oura itself is offering 13.5 million and existing stockholders are offering the remaining 36.5 million, with the company receiving no proceeds from the stockholder portion; the selling stockholders also intend to grant underwriters a 30-day option to purchase up to 7.5 million additional shares. The offering targets a fully diluted valuation of $15.62 billion, and the company has applied to list on the Nasdaq Global Select Market under the ticker symbol OURA, with trading expected to begin next week. Eli Lilly has signaled it may buy up to $100 million worth of shares, while investment firm Dragoneer has expressed interest in acquiring up to $300 million worth, and the lead underwriters are Goldman Sachs, Morgan Stanley, and J.P. Morgan, with Allen & Company and Jefferies acting as joint lead book-running managers. According to its IPO prospectus, Oura moved 3.6 million rings in the year through June 30, with revenue hitting $1.21 billion for the nine months ended on that date, a roughly 74% jump from the same period a year earlier, and the company projects its paid membership base will reach approximately 5.7 million by the close of fiscal 2026. The IPO follows a late-stage funding round last October that brought in $900 million and pushed Oura's valuation to $11 billion, and it arrives as the company defends against a proposed class-action lawsuit filed in August alleging its ring cannot measure sleep stages with the accuracy claimed in its marketing.
Oura Health · Capital · Positive Oura launched its IPO roadshow aiming to raise up to $2.2 billion at a $15.62 billion valuation.
Oura Health · Regulation · Negative Oura is defending against a proposed class-action lawsuit alleging its ring cannot measure sleep stages as accurately as marketed.
LLY · Capital · Positive Eli Lilly signaled it may buy up to $100 million worth of Oura shares in the IPO, a financial investment.
Novo Rebrands as Novo, Lilly Wins FDA Nod, GE HealthCare Nears $1B Sofie Deal
Novo Nordisk will shorten its name to Novo and update its logo, with its trademark bull shifting to face right, as the Danish drugmaker battles Eli Lilly for dominance in the obesity-drug market. CEO Mike Doustdar is pushing to make Novo leaner and more competitive, and the company will detail its updated corporate strategy at a Capital Markets Day on September 21 in London. Separately, Eli Lilly said the U.S. FDA granted full approval for an all-oral regimen combining its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line option for adults with estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation whose disease progressed after one or more prior endocrine therapies. GE HealthCare Technologies is in advanced talks to acquire Sofie Biosciences for about $1 billion, a deal that would expand its presence in radioactive diagnostic agents used with medical scans, according to the Financial Times. Summit Therapeutics said ivonescimab reduced the risk of death by 27% versus Merck's Keytruda in a late-stage lung cancer trial, with median overall survival of 30.8 months versus 22.6 months. Medtronic launched an exchange offer to split off at least 80.1% of MiniMed Group, allowing shareholders to exchange ordinary shares for MiniMed common stock at a 7% discount.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▼Competition
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Capital
Biotech & Genomic Medicine › Diabetes Devices (CGM & Insulin Delivery) Capital
GEHC · Capital · Positive GE HealthCare in advanced talks to acquire Sofie Biosciences for about $1 billion, expanding its radioactive diagnostic agents business.
LLY · Regulation · Positive FDA granted full approval for Lilly's all-oral Inluriyo plus Verzenio regimen for ESR1-mutant ER-positive, HER2-negative breast cancer.
MDT · Capital · Positive Medtronic launched an exchange offer to split off at least 80.1% of MiniMed Group at a 7% discount.
NVO · Capital · Neutral Novo rebrands and shortens name to Novo, with CEO pushing to make it leaner and more competitive ahead of a Sept 21 Capital Markets Day strategy update.
Sofie Biosciences · Capital · Positive GE HealthCare is in advanced talks to acquire Sofie Biosciences for about $1 billion, expanding its radioactive diagnostic agents business.
MMED · Capital · Positive MiniMed is being split off from Medtronic via an exchange offer at a 7% discount, creating its own public listing.
Eli Lilly Fair Value Rises to US$1,325.39 as Analysts Back GLP-1 Growth
Eli Lilly's updated fair value estimate has shifted from US$1,297.31 to US$1,325.39, with revenue growth moving from 13.98% to 14.17%, net profit margin from 41.26% to 42.01%, and future P/E from 28.66x to 28.85x, while the discount rate held at 7.24%. The revision sits alongside analyst price targets that often exceed US$900, with a cluster between US$1,300 and US$1,600, as firms including Citi, BMO Capital, RBC Capital, UBS, Morgan Stanley, Bernstein, Truist, Cantor Fitzgerald, BofA, Leerink and Berenberg raised targets into a range stretching from around US$1,135 to US$1,600. Guggenheim lifted its target to US$1,284, incorporating updated prescription and pricing assumptions and the reinstatement of Zepbound on the CVS formulary, while HSBC kept a Reduce rating even after raising its target to US$940, citing elevated sector multiples. The U.S. FDA granted full approval for Eli Lilly's Inluriyo in combination with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy, based on Phase 3 EMBER-3 data showing the combination doubled median progression-free survival versus Inluriyo alone. Eli Lilly also plans to present data on Mounjaro, Zepbound, Foundayo, retatrutide and eloraTZP at the European Association for the Study of Diabetes 2026 meeting in Milan, and Berenberg upgraded the stock citing weight-loss drug growth prospects, a pipeline described through 2030, and around US$60b committed to more than 25 business development deals this year, including acquisitions in sleep and cancer.
FDA Grants Full Approval to Lilly's Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
Eli Lilly and Company announced that the U.S. Food and Drug Administration has granted full approval to Inluriyo, or imlunestrant, in combination with Verzenio, or abemaciclib, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The decision rests on the Phase 3 EMBER-3 trial, in which the combination doubled median progression-free survival versus Inluriyo alone, at 11.1 months versus 5.5 months, with a hazard ratio of 0.53 and a 95% confidence interval of 0.35 to 0.80, among the 159 patients with ESR1-mutated metastatic breast cancer. In that trial, 92 patients received Inluriyo alone and 67 received the combination after an aromatase inhibitor, with or without a CDK4/6 inhibitor, in either the adjuvant or metastatic setting. The approval marks the second FDA clearance for Inluriyo in less than a year, following its September 2025 monotherapy approval for the same ER-positive, HER2-negative, ESR1-mutated metastatic population. Inluriyo is also being studied in the Phase 3 EMBER-4 trial in the adjuvant setting for ER-positive, HER2-negative early-stage breast cancer, the largest adjuvant oral SERD trial with more than 8,000 patients enrolled across 650-plus sites in more than 30 countries, with initial results anticipated in 2027. The combination is now available in the United States.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Competition
LLY · Regulation · Positive FDA granted full approval to Inluriyo plus Verzenio for ESR1-mutated breast cancer, expanding Lilly's approved oncology offering.
Novo Nordisk CEO Mike Doustdar Resets Obesity Strategy With "Novo Way"
Novo Nordisk CEO Mike Doustdar is resetting the drugmaker's culture and competitive focus under a new "Novo Way" emphasizing customer focus, competitiveness, clarity and care, as the company rebrands to the day-to-day name "Novo" after losing ground to Eli Lilly in obesity drugs. Novo pioneered the modern obesity-drug market with Wegovy in the U.S. in 2021, but Eli Lilly has since gained ground with Zepbound and more aggressive consumer-focused commercialization. Novo has moved into oral obesity treatment with its Wegovy pill, and expects oral drugs to account for more than one-third of GLP-1 obesity-treatment use by 2030; analysts expect the U.S. obesity-treatment market to exceed $100 billion annually by 2030. Novo's Wegovy pill had captured roughly 90% of the U.S. oral-obesity market as of August, although Lilly subsequently said its Foundayo treatment had already captured more than 30% of new U.S. oral-treatment patients. Doustdar's message is that Novo must operate differently to defend and expand its position, and the company's September 21 capital-markets day should show investors how the "Novo Way" will translate into stronger competitive performance.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
NVO · Competition · Neutral Novo is resetting strategy under 'Novo Way' to defend its obesity franchise after losing ground to Eli Lilly, with its Wegovy pill holding ~90% of the U.S. oral-obesity market.
LLY · Competition · Positive Lilly's Zepbound and Foundayo are gaining ground on Novo, with Foundayo already capturing over 30% of new U.S. oral-treatment patients.
USA
